标签: Asia

亚洲

  • Netanyahu hints at US troop deployment against Iran in CBS interview

    Netanyahu hints at US troop deployment against Iran in CBS interview

    In a televised interview with CBS’s iconic news program *60 Minutes* that aired Sunday evening, Israeli Prime Minister Benjamin Netanyahu has raised the possibility of deploying United States ground forces inside Iranian territory, confirming that the ongoing Middle East crisis is far from over. Netanyahu argued that on-the-ground military operations would be required to seize and secure Iranian nuclear material, though he declined to share any specific timeline for when such an operation might be launched.

    “I’m not going to discuss specific military tactics, but what President Trump told me is that he is prepared to go in,” Netanyahu stated in the interview, adding that he believes a ground incursion is physically achievable. This current conflict, widely viewed as having been orchestrated by Netanyahu, first erupted in late February when a joint surprise strike by U.S. and Israeli forces targeted multiple sites across Iran, including Iranian political leadership hubs, a girls’ school, and key military infrastructure.

    According to reporting from multiple U.S. media outlets, U.S. President Donald Trump did not anticipate the initial wave of attacks would fail to force Iran to surrender. Contrary to Trump’s expectations, Tehran mounted a fierce resistance campaign against the U.S.-Israeli coalition: it targeted American military bases across the Persian Gulf, struck Israeli military infrastructure, and blocked all commercial traffic through the Strait of Hormuz, the world’s most critical energy chokepoint that carries roughly 20% of global oil supplies.

    Trump negotiated a ceasefire with Iran on April 8, but subsequent talks have failed to produce a permanent end to hostilities. Iranian public and political sentiment remains deeply skeptical of the U.S. and Israel, with widespread belief that the coalition will resume attacks once it has regrouped and replenished its military capabilities.

    In a surprising announcement during the interview, Netanyahu also said he favors ending the long-standing annual U.S. military aid package to Israel, which currently stands at $3.8 billion per year and balloons substantially during periods of open conflict. In place of traditional aid, Netanyahu proposed a new bilateral military partnership under which the U.S. would share advanced weapons technology with the Israeli military.

    This proposal comes amid growing criticism within the U.S. over Israel’s outsized influence over American foreign policy and its decades-long reliance on U.S. military funding. While establishment politicians on both sides of the aisle continue to express unwavering support for Israel, American public opinion has shifted sharply against the country in recent months. A Gallup poll conducted in February found that 41% of U.S. adults now hold more sympathetic views of Palestinians, compared to just 36% who sympathize more with Israel. This marks a dramatic reversal from 2023, when 54% of respondents sympathized more with Israel and only 31% leaned toward Palestinians.

    On social media and in public discourse, three key factors are most frequently cited to explain the shift in U.S. public opinion: the ongoing humanitarian crisis and allegations of genocide in Gaza, Israel’s extensive lobbying efforts to influence U.S. political decision-making, and Israel’s long track record of pushing the U.S. to enter into foreign wars that primarily serve Israeli interests.

  • Elon Musk and Tim Cook among CEOs expected to accompany Trump on China trip

    Elon Musk and Tim Cook among CEOs expected to accompany Trump on China trip

    As Washington prepares for a high-stakes official visit to Beijing this week, U.S. President Donald Trump is set to be accompanied by an unprecedented roster of 17 chief executives from America’s most influential business and technology sectors, according to a senior White House official familiar with the travel itinerary who spoke to the BBC.

    The lineup of corporate leaders joining the presidential delegation includes some of the most high-profile names in global industry: Apple CEO Tim Cook, Tesla and SpaceX founder Elon Musk, and BlackRock Chairman and CEO Larry Fink, alongside senior representatives from other major American firms spanning technology, finance, aviation, and agriculture. These additional companies include tech giant Meta, global payments processor Visa, leading investment bank JP Morgan, aerospace manufacturing leader Boeing, and agribusiness conglomerate Cargill, among others.

    The four-day state visit comes at a particularly consequential juncture for bilateral relations between the world’s two largest economies, with mounting frictions over trade, market access, and technological competition creating heightened tensions in recent months. During the trip, President Trump is scheduled to hold formal bilateral talks with Chinese President Xi Jinping, with the business delegation’s presence widely interpreted as a signal of Washington’s priority on expanding commercial opportunities for U.S. companies in the Chinese market while addressing longstanding bilateral economic and trade concerns.

    Analysts note that the inclusion of so many top C-suite leaders from key sectors underscores the depth of American corporate interest in stabilizing U.S.-China economic ties, even as geopolitical and technological disagreements continue to test the bilateral relationship. For both governments, the meeting is seen as a critical opportunity to ease escalating tensions and open new pathways for constructive engagement on shared economic and trade priorities.

  • Israel kills three, including police officers, in latest Gaza truce violation

    Israel kills three, including police officers, in latest Gaza truce violation

    Fresh Israeli military operations across the Gaza Strip have left three Palestinians dead, including two local police officers, marking the latest breach of the U.S.-brokered ceasefire agreement reached in October 2024. In an official announcement released Sunday, Gaza’s General Directorate of Police confirmed that an Israeli air strike targeted the vehicle of senior police official Wissam Abdel Hadi, director of the Khan Younis Police Investigations Department, and Sergeant Fadi Heikal in the al-Amal neighborhood of southern Gaza. The attack also left an unspecified number of additional Palestinians wounded. Hamas, the governing authority in Gaza, issued a sharp condemnation of the strike, framing the deliberate targeting of Gaza’s police force as an ongoing campaign of criminal violence and state-sponsored terrorism against the Palestinian people. The movement argued that these attacks are intentionally designed to entrench lawlessness, spread widespread chaos, and block all efforts to rebuild civilian infrastructure and restore normal daily life to the blockaded enclave. Hamas has called on the international community to exert meaningful pressure on Israel to end its ongoing military assaults on Palestinian civilians and security personnel. Sunday’s targeted killing of two police officers is not an isolated incident, but the most recent in a consistent pattern of Israeli attacks on Gaza’s official security forces. The strikes come at a sensitive moment, as regional stakeholders hold ongoing discussions about the potential formation of a new unified police force to maintain order in the blockaded territory. In addition to the police officers, a third Palestinian was killed and multiple other people – including two minor children – were injured in separate attacks across Gaza over the 24-hour reporting period. Anadolu Agency, citing an anonymous medical source, reported that an Israeli drone strike targeted a group of civilian residents gathered in the al-Maghazi refugee camp in central Gaza. A key detail that underscores the ceasefire violation is that both the southern and central Gaza strikes took place outside the existing deployment lines of Israeli ground troops, in an area located beyond the so-called “Yellow Line” – a unilateral military boundary Israeli forces established inside Gaza after the October ceasefire took effect. The Yellow Line is designated as a no-go zone for Palestinians, barring local residents from accessing large swathes of agricultural and residential land across the northern, southern, and eastern edges of the enclave. While the terms of the October truce required Israeli forces to withdraw from territory behind this boundary, Israeli authorities have instead steadily expanded the zone, bringing previously accessible civilian areas under Israeli fire control and resulting in growing numbers of dead and wounded civilians in territory Israel did not control immediately after the ceasefire. In additional incidents reported Monday, Israeli ground forces opened fire on displaced Palestinian civilians sheltering in northern Gaza and Gaza City. Off the coast of Gaza City, Israeli naval forces shelled a group of Palestinian fishermen working in their traditional fishing grounds, wounding an unspecified number of the workers. Local reports confirm that naval personnel also arrested at least six of the fishermen, and their current whereabouts and physical condition remain unknown to family members as of press time. Recent official data from Gaza’s Ministry of Health shows that since the October ceasefire went into effect, at least 854 Palestinians have been killed by Israeli military actions across the enclave, with more than 2,540 others suffering injuries. Since the start of Israel’s large-scale military campaign in Gaza in October 2023, the total death toll has surpassed 72,740 Palestinians killed, according to the latest official counts. Thousands more Palestinians remain missing and are presumed dead, trapped under the rubble of destroyed residential and civilian buildings across the strip. This report was compiled by Middle East Eye, an outlet that provides independent, on-the-ground coverage of the Middle East, North Africa, and global affairs.

  • Hantavirus scare exposes US-China mRNA gap

    Hantavirus scare exposes US-China mRNA gap

    In late May 2026, a dramatic incident unfolded at sea that has reframed global conversations about pandemic preparedness and biotech investment: the Dutch expedition cruise ship MV Hondius, which had been adrift for weeks amid a growing public health emergency, finally docked in Tenerife. By the time the vessel reached port, three people had died from the outbreak, and eight passengers and crew had tested positive for Andes virus, a strain of hantavirus. Critically, this is the only known hantavirus variant that can spread between people. While the World Health Organization has labeled the outbreak a serious cluster, the organization has assessed the overall global risk of widespread transmission as low.

    This small but deadly scare offers more than just a reminder of emerging pathogens; it holds a valuable lesson for global health strategy that extends far beyond hantavirus itself. When any new or little-known pathogen surfaces, public discourse too often swings to unhelpful extremes: either widespread panic or outright dismissal. Hantavirus deserves neither. While it can be lethal in symptomatic cases, it does not spread at the same rate as influenza or SARS-CoV-2, the virus that caused the COVID-19 pandemic. It is precisely this low but persistent risk that makes it a perfect case study for how countries should approach future health threats.

    The core takeaway from this incident is not that the world needs to rush a hantavirus vaccine into mass distribution immediately. Instead, it highlights that modern vaccine development platforms represent a critical form of strategic health insurance – and countries around the world are now valuing this insurance in dramatically different ways.

    Hantavirus vaccine research is still in its early stages. Biotech firm Moderna has already disclosed preclinical and early-stage work on a candidate, developed in partnership with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University. Still, public health experts uniformly caution that a fully approved, widely available hantavirus vaccine is likely years away without an extraordinary coordinated global push. This combination – low immediate outbreak risk, high potential catastrophic consequence, and limited commercial market incentive – is exactly the space where intentional public policy becomes indispensable.

    Against this backdrop, the growing divergence in mRNA technology strategy between China and the United States has become impossible to ignore. China has framed mRNA not merely as a short-term technology for the COVID-19 pandemic, but as a flexible, general-purpose platform that can advance everything from infectious disease control to oncology, while also supporting Beijing’s goal of biomedical sovereignty.

    Today, China’s domestic mRNA development pipeline spans multiple high-priority areas: cancer immunotherapy, influenza vaccines, respiratory syncytial virus (RSV) preventives, and countermeasures for emerging pathogens. The country has steadily expanded investment in core enabling technologies, including lipid nanoparticle delivery systems and AI-assisted antigen sequence design. In 2023, China approved its first domestically developed mRNA COVID-19 vaccine, establishing a critical domestic manufacturing baseline even though the approval came after the first major global wave of the pandemic.

    The United States, by contrast, is moving in the opposite direction. In August 2025, the U.S. Department of Health and Human Services announced it would wind down mRNA vaccine development projects administered by the Biomedical Advanced Research and Development Authority (BARDA), terminating 22 separate projects that represented nearly $500 million in public investment.

    Administration officials framed the decision as a strategic redirection, arguing that public funds would be better allocated to platforms with more proven track records against upper respiratory viruses. But many leading vaccine scientists have criticized the move as a damaging strategic retreat from a transformative technology that the United States itself originally pioneered.

    This trend is not a simple narrative of China rising and America retreating. The U.S. still retains unmatched global advantages in biomedical innovation: world-leading research universities, a rigorous regulatory system, deep capital markets, and decades of advanced manufacturing expertise. It also has legitimate policy reasons to scrutinize public spending, require rigorous evidence of efficacy, and avoid framing any single technology as a cure-all.

    For its part, China still faces significant structural challenges in expanding its mRNA ecosystem: questions around regulatory credibility, transparency of clinical data, uneven global public trust, and the ongoing difficulty of translating pipeline projects into safe, effective products that gain widespread international acceptance. Still, the divergence in long-term strategic framing between the two powers is clear and consequential.

    China’s policy approach centers on a core question: how can mRNA be embedded into a sustained long-term strategy for industrial development and national health security? The U.S. approach, by contrast, centers on a different question: how much public support for mRNA remains politically and fiscally justifiable in the aftermath of the COVID-19 pandemic? These different starting questions lead to vastly different long-term outcomes for global health.

    The deeper misstep in global discussions of mRNA is that the technology is almost always framed too narrowly. mRNA is not just a new type of vaccine. It is a programmable manufacturing platform for biological products. Once a country has established core infrastructure – reliable delivery platforms, accumulated safety data, scalable production lines, standardized quality controls, and established regulatory pathways – developing a new product for a new target can be accomplished far faster than with most traditional vaccine development approaches.

    This inherent speed does not eliminate the hard work of rigorous science. Any vaccine candidate still needs to identify the correct antigen, generate long-lasting durable immunity, prove safety through large-scale trials, and navigate clinical testing challenges that are particularly acute for rare, sporadic outbreaks. But a country that maintains a standing, robust mRNA ecosystem starts the race to counter a new threat several laps ahead of nations that treat the platform as an emergency tool to be built from scratch only after a crisis hits.

    The most productive way to frame the global mRNA conversation is to stop treating it as a narrow debate about vaccines. Instead, it is more accurately compared to the global race for semiconductor leadership. Nations do not invest billions in semiconductor design and manufacturing capacity because they know exactly which specific chips they will need a decade from now. They invest because having domestic design capacity, fabrication infrastructure, skilled talent, and resilient supply chains creates critical strategic options that can be adapted to whatever demand emerges.

    mRNA offers exactly the same kind of option value for global health. It enables faster responses to newly emerging viruses, more adaptable annual influenza vaccines, individualized cancer immunotherapies, and targeted countermeasures for threats that are too small to attract commercial investment but too dangerous to leave unaddressed.

    This is why the comparison between Chinese and U.S. strategy should not be framed as a simplistic ideological competition. Instead, it should be viewed as a lesson in institutional learning. China can learn from the U.S. model that breakthrough biomedical science depends on open inquiry, rigorous peer review, strictly controlled clinical trials, and building global public trust in data. The U.S., in turn, can learn from China that transformative platform technologies require sustained investment in long-term infrastructure, not just episodic emergency funding during acute crises.

    Both nations can benefit from the shared lesson that global biomedical leadership is not won through slogans and political posturing. It is secured through unglamorous, durable systems: a well-trained workforce, reliable public procurement pathways, transparent clinical data, flexible scalable manufacturing, and sustained public trust in health institutions.

    A balanced, effective policy approach avoids two dangerous extremes. The first is undisciplined blanket funding for every mRNA candidate, assuming all projects deserve public backing regardless of evidence. The second is a full retreat from the platform, driven by post-COVID political fatigue, unmet early expectations, or narrow metrics that obscure the broader long-term value of the ecosystem. Even the most common critique of COVID-19 mRNA vaccines – that vaccinated people could still contract and transmit the virus – misses the core point: the primary benefit of those shots was always their ability to prevent severe disease, hospitalization, and death, a goal they achieved with remarkable success.

    For countries across Asia, the implications of this divergence are immediate and actionable. Nations do not need to choose between aligning with the U.S. or Chinese model. Instead, they can pursue a middle path of building regional mRNA manufacturing capacity, participating in multinational clinical trials, requiring transparent public data from all developers, and negotiating technology partnerships that reduce dependence on any single global power. The end goal should not be divisive vaccine nationalism. It should be widespread vaccine optionality: the ability to respond rapidly to whatever threat emerges.

    It is unlikely that hantavirus will ever become the next global pandemic. In fact, the world should hope it never does. But the next unexpected pathogen, the next breakthrough cancer therapy, or the next major respiratory virus threat will test whether countries used the post-COVID years to build durable adaptive platforms – or merely spent that time re-litigating the last crisis.

    China is investing heavily as if mRNA is a core part of the world’s long-term health future. The United States would be wise to avoid treating one of its own most transformative scientific breakthroughs as nothing more than a temporary tool for wartime emergency. The real question at stake is not which country will win an mRNA race. It is whether the world will have enough trusted, distributed, and adaptable biomedical capacity when biology surprises us again. This article was written by Y. Tony Yang, an Endowed Professor at the George Washington University in Washington, DC.

  • Trump-Xi meet more about US uncertainty than China ambition

    Trump-Xi meet more about US uncertainty than China ambition

    As U.S. President Donald Trump prepares to touch down in Beijing this week for high-stakes talks with Chinese President Xi Jinping, the choreographed opening moments of the summit are already predictable: firm, photographed handshakes, sweeping rhetorical claims, carefully staged symbolic gestures, and mutual declarations of unlocking new “historic” economic cooperation. But behind this carefully curated diplomatic spectacle lies a far more consequential shift reshaping the geopolitical future of the Indo-Pacific.

    Donald Trump’s second term in office has not delivered a cohesive new U.S. doctrine for the Indo-Pacific. Instead, it has amplified longstanding American strategic anxieties into a louder, purely transactional approach that departs sharply from the frameworks built by his two immediate predecessors. For more than a decade, successive U.S. administrations have framed the Indo-Pacific as the global center of geopolitical gravity. Barack Obama’s “pivot to Asia” was designed to reassure regional allies that Washington recognized the region’s growing strategic weight. Joe Biden built on that foundation, expanding the framework through minilateral security pacts, technology alliances, and targeted diplomatic engagement crafted to balance China’s rise without triggering open conflict.

    Trump’s second term marks a clear break from this trajectory. While the current administration has retained most of Washington’s hard-line rhetoric toward Beijing, it has abandoned the broader diplomatic and institutional architecture that once sustained U.S. credibility across the region. Instead, the Trump 2.0 approach relies heavily on economic nationalism, repeated tariff threats, and demands for increased defense burden-sharing from allies already navigating mounting geopolitical and financial volatility. Despite the administration’s claims of strategic renewal, this strategy largely repackages long-running U.S. anxieties about China into a more confrontational doctrine centered on trade escalation, economic coercion, and increasingly inflammatory rhetoric around global great-power competition.

    This shift has left regional governments viewing Washington through an increasingly transactional lens. U.S. allies and partners face repeated calls to decouple their supply chains from China, even as they confront new American tariffs, industrial policy disputes, and growing uncertainty about the durability of long-term U.S. commitments to the region.

    This ambiguity matters deeply, because most middle powers in Asia have no interest in being forced to choose between Washington and Beijing. The vast majority of regional governments seek to retain strategic flexibility, diversified trade relationships, and stable security arrangements that avoid dividing the region into rigid, opposing blocs. Vietnam offers a clear illustration of this common regional dilemma. Over the past decade, Hanoi emerged as one of the biggest beneficiaries of global supply chain diversification, as manufacturers shifted production out of China amid escalating U.S.-China tensions. American firms were major drivers of this shift. Yet today, Washington increasingly frames Vietnam’s export growth through a narrative of “overcapacity” and industrial imbalance, even though most of Vietnam’s manufacturing sector is powered by multinational investment, not state-directed dumping. This contradiction has not been lost on regional capitals, nor has the growing gap between Washington’s military posture and its diplomatic messaging.

    The U.S. continues to carry out freedom of navigation operations in the South China Sea, deepen defense ties with regional allies, and strengthen deterrence frameworks around Taiwan. But military posturing alone does not add up to a cohesive regional strategy. Diplomatic engagement, economic integration, and institutional trust remain equally critical pillars of influence in Asia. That power vacuum is an opening Beijing has been quick to exploit. China’s leadership understands that regional influence today depends not just on naval power, but on infrastructure financing, deep trade relationships, development assistance, and increasingly, environmental diplomacy and ocean governance.

    Beijing’s bid to host the secretariat for the new UN High Seas Treaty is a perfect example of this broader strategy. China has positioned itself as a responsible steward of the global maritime commons, pledging financial support for marine conservation projects while expanding its diplomatic footprint across developing coastal states. To be sure, many regional governments remain deeply cautious of China’s strategic intentions, particularly in the South China Sea, where gray zone tactics, maritime coercion, and unresolved territorial disputes continue to erode trust. But Beijing does not need to be fully consistent in its own policies to displace American influence; it only needs to capitalize on growing perceptions of inconsistency in U.S. policy. Trump’s return to the White House has only amplified these perceptions. The administration’s focus on tariffs and economic confrontation risks undermining the very partnerships Washington needs to sustain long-term strategic competition with China.

    Regional leaders hear constant demands to align with Washington against Beijing, even as they watch the U.S. withdraw from many of the multilateral trade frameworks and regional agreements that once anchored American economic leadership in Asia. At the same time, Xi Jinping enters the upcoming summit with key advantages that extend far beyond diplomatic positioning. While China’s economy is experiencing slower growth, Beijing retains enormous leverage across regional supply chains, manufacturing networks, and infrastructure financing. It can restrict exports of critical rare earth minerals, which are essential for defense systems, electric vehicles, and a wide range of everyday modern products. It continues to invest heavily in advanced technologies, maritime capabilities, and strategic industries that will define future great-power competition.

    Xi has projected consistent policy continuity in Asia, anchored by long-term planning and institutional discipline – qualities that many regional governments value greatly, even when they remain wary of Beijing’s long-term ambitions. For instance, the Belt and Road Initiative, for all the criticism it has drawn, projects permanence through ports, railways, energy projects, and long-term financing commitments that unfold over decades. Chinese diplomacy also prioritizes patience and gradualism. Even when Beijing acts assertively in the South China Sea or the Taiwan Strait, it typically frames those actions within a broader narrative of historical continuity and national rejuvenation. This consistency holds unique weight in Asia, where political stability and policy predictability are often valued as much as ideological alignment. While many regional governments still do not fully trust Beijing, a growing number are questioning whether U.S. policy can remain durable beyond U.S. electoral cycles and the shifting priorities of individual political leaders.

    Against this backdrop, Trump’s Beijing visit carries significance that stretches far beyond bilateral U.S.-China relations. The summit will serve as a critical test of whether Washington can still articulate a broad, cohesive Indo-Pacific vision that goes beyond tariffs, confrontation, and occasional displays of military strength. It will also reveal whether the U.S. still understands that regional influence depends not just on containing China, but on offering regional partners a credible, stable, and economically attractive alternative to Beijing’s model. The core risk for Washington is not that Asia will suddenly align fully with China. It is that the region will gradually adapt to a new order where U.S. policy appears unpredictable, excessively transactional, and increasingly disconnected from the long-term economic and political realities shaping the Indo-Pacific. This kind of strategic drift would benefit Beijing far more than any joint summit communique or carefully staged diplomatic performance.

    Trump will arrive in Beijing seeking to project American strength. But most regional observers will be watching for a far more critical marker: whether the U.S. still possesses the strategic patience and political coherence required to sustain leadership in the Indo-Pacific. Right now, the answer to that question remains deeply uncertain. This analysis is contributed by James Borton, editor-in-chief of the South China Sea NewsWire, co-author of the recently released SCSNW Indo-Pacific Report, with contributions from managing editor David Hessen.

  • Police find body believed to be of fugitive Australian shooter

    Police find body believed to be of fugitive Australian shooter

    Four months after a horrific triple shooting that left three people dead — including a seven-month pregnant woman — in the small Australian outback town of Lake Cargelligo, authorities have confirmed the discovery of a body believed to be that of the prime suspect, Julian Ingram.

    The tragedy dates back to January 22, when Ingram, a local council worker who had been granted bail on prior domestic violence offences, allegedly opened fire on his ex-partner Sophie Quinn, who was expecting a child due in March, Quinn’s close friend, and Quinn’s aunt. All three died at the scene. A 19-year-old man who was also attacked in the shooting survived with serious injuries and has since been discharged from hospital, police confirmed.

    In the immediate aftermath of the killings, law enforcement launched a massive manhunt, deploying roughly 100 officers to scour the remote region surrounding Lake Cargelligo, a community of just 1,500 residents located around 450 kilometres west of Sydney. Assistant Commissioner Andrew Holland noted at the time that Ingram’s long-term work in the area had given him intimate local knowledge, allowing him to stay off the grid for an extended period. He was not spotted after the day of the shootings.

    The breakthrough came when wildlife officers conducting routine feral pest eradication operations stumbled across the remains 50 kilometres northwest of the murder site, next to an abandoned utility vehicle. On Monday, Holland told reporters that forensic and on-site checks have already linked the vehicle to Ingram. “Based on the identification evidence from the scene and the clothing the deceased was wearing, we are confident this is Julian Ingram,” Holland told reporters, according to Australian public broadcaster ABC.

    Investigators added that the body appeared to have been left at the remote location for a significant amount of time, consistent with Ingram having disappeared shortly after the January attacks. For the tight-knit community of Lake Cargelligo that has lived under the shadow of the unsolved case for months, the discovery marks a pivotal turning point. Holland said the finding brings a formal close to the active investigation, and can offer some measure of comfort to a shaken town, allowing residents to finally move forward after the tragedy.

  • Trump-Xi summit comes with high stakes for Taiwan, the island democracy that China claims as its own

    Trump-Xi summit comes with high stakes for Taiwan, the island democracy that China claims as its own

    As U.S. President Donald Trump prepares for his high-stakes summit with Chinese President Xi Jinping this week, growing ambiguity around his approach to Taiwan has sparked intense speculation across global capitals about the future of long-standing U.S. policy toward the self-governing island that Beijing claims as its own.

    Trump’s actions and public comments have painted a contradictory picture in recent months. In December last year, he approved a historic $11 billion arms package for Taiwan – the largest single weapons deal the U.S. has ever concluded with the island. To date, however, no delivery timeline has been finalized, and Trump has publicly confirmed he has already discussed the proposed sale with Xi. Beyond the arms deal debate, the U.S. leader has publicly complained that Taiwan “stole” American semiconductor industry business, and has repeatedly pressured Taipei to compensate Washington for its security commitments. Using the threat of steep new tariffs as leverage, Trump has also pushed Taiwan to commit to large-scale investments in U.S.-based advanced semiconductor manufacturing, and to purchase billions of dollars in American crude oil and liquefied natural gas.

    This inconsistent approach has left policymakers and analysts in Beijing, Taipei, and Washington questioning the durability of the U.S.’s long-held commitment to Taiwan’s self-defense. Critics, particularly among Washington’s foreign policy circles that back strong U.S. support for Taipei, warn that Trump’s transactional approach to diplomacy could leave Taiwan vulnerable to concessions during the summit. Retired U.S. Navy Rear Admiral Mark Montgomery, now a senior fellow at the Foundation for Defense of Democracies, noted that supporters of Taiwan are growing increasingly concerned that the island could become a bargaining chip in talks between the two global leaders.

    For its part, Beijing has made clear that the Taiwan issue will be a central topic of discussion during this week’s meetings. Chinese Foreign Minister Wang Yi raised the island’s status during a pre-summit call with U.S. Secretary of State Marco Rubio, urging Washington to “make the right choices” on Taiwan policy to preserve bilateral stability, according to an official statement from the Chinese Foreign Ministry. While Rubio reaffirmed in a press briefing in Rome that long-standing U.S. policy has not shifted – stating Washington opposes any forced changes to the cross-strait status quo that would threaten global stability – he did acknowledge that Taiwan would feature on the summit’s agenda, even if it is not a formal centerpiece.

    White House officials have pushed back against concerns over shifting policy, pointing out that Trump has already approved more military sales to Taiwan in the first year of his second term than former Democratic President Joe Biden approved across his full four-year term. In addition to the $11 billion arms package, Trump greenlit a $330 million deal for military aircraft parts for Taiwan in November. The Trump administration has also long pressured Taipei to increase its own defense spending, a goal that saw partial progress Friday when Taiwanese lawmakers ended months of legislative gridlock to approve a $25 billion arms purchase budget. That figure fell far short of the $40 billion proposal put forward by Taiwanese President Lai Ching-te, a gap that a senior anonymous Trump administration official called disappointing.

    Taiwanese officials have publicly acknowledged concern over Beijing’s intensified rhetoric ahead of the summit, though they have drawn some reassurance from Rubio’s recent comments. National Security Bureau Director-General Tsai Ming-yen told reporters that while Beijing may attempt diplomatic maneuvering during the talks, Washington has repeatedly confirmed through both public and private channels that its Taiwan policy remains unchanged.

    China analysts note that Xi’s core goal will be to pressure Trump to roll back elements of U.S. support for Taipei, aligned with Beijing’s long-standing position that Taiwan is a breakaway province that must eventually be reunified with the mainland, by force if necessary. Since 1979, the U.S. has maintained a policy of “strategic ambiguity”: it acknowledges Beijing’s claim that Taiwan is part of China, but does not explicitly endorse that position, opposes Taiwanese independence, rejects unilateral changes to the status quo, and provides informal security support and arms to Taipei.

    Analysts say Xi will likely push Trump to curb U.S. arms sales and impose informal restrictions on high-level U.S. official visits to the island, taking advantage of Trump’s already demonstrated willingness to deviate from traditional diplomatic norms. In February, Trump made headlines by confirming he consults Xi on U.S. arms sales to Taiwan, breaking with decades of established policy. Patricia Kim, a China expert with the Brookings Institution’s Assessing China Project, warned that even if no formal policy shift is announced, Trump’s well-documented tendency to make off-the-cuff remarks could create unintended shifts that upend cross-strait stability.

    Uncertainty over the U.S. commitment has also been amplified by Trump’s muted response to a recent diplomatic rift between U.S. ally Japan and China over Taiwan. In November, Japanese Prime Minister Sanae Takaichi said a Chinese attack on Taiwan would constitute a regional security threat that could qualify as a “survival-threatening situation” for Japan, justifying a military response. Trump spoke with both Takaichi and Xi that same month, but has largely avoided taking a public stance on the dispute, noting in March talks with Takaichi that he would “be speaking Japan’s praises when I’m in China with President Xi.” Additional scrutiny came after the 2026 U.S. National Defense Strategy omitted any direct mention of Taiwan.

    Still, many analysts point to one key factor that may protect Taiwan from major policy shifts: its dominant position in the global semiconductor industry, a sector critical to U.S. technological competitiveness in its race with China. Lev Nachman, a political science professor at National Taiwan University, noted that Trump is well aware of Taiwan’s central role to U.S. economic and technological growth, creating a baseline that makes drastic policy shifts unlikely.

    Edgard Kagan, a former senior State Department official who worked on East Asia policy for both the Trump and Biden administrations and now holds the China Studies chair at the Center for Strategic and International Studies, added that while Trump approaches diplomacy from a transactional perspective, his administration has never treated core U.S. interests in the region as negotiable trade-offs. “The president understands leverage. My experience of being in meetings with him, he has a very, very acute sense of how to use it,” Kagan said. “And so I think that the idea that there’s going to be a trade where the president sort of sacrifices U.S. interests in Taiwan in order to get other things — I think it’s unlikely based on my own experience of how he operates.”

    In the end, the outcome of the summit for Taiwan will likely be measured by the public statements the two leaders release. After Trump’s last in-person meeting with Xi in October, he claimed the Chinese leader had not raised the Taiwan issue, and that Chinese officials “know the consequences” of any military action against the island. For Taipei, Nachman noted, the best possible outcome is that the issue is not discussed publicly, or addressed only in passing.

  • Philippine VP Sara Duterte impeached for a second time

    Philippine VP Sara Duterte impeached for a second time

    In a major development reshaping Philippine politics, the House of Representatives has approved a second impeachment vote against Vice President Sara Duterte, clearing the way for a Senate trial that could permanently end her presidential ambitions for the 2028 election.

    Monday’s vote crossed the required one-third threshold easily, with 255 out of 290 attending lawmakers backing the impeachment move. The case centers on two core allegations: unauthorized misuse of public funds during Duterte’s tenure as vice president, and public threats she made against President Ferdinand Marcos Jr., First Lady Liza Araneta Marcos, and former House Speaker Martin Romualdez.

    This is not the first time impeachment proceedings have been brought against Duterte on identical grounds. The first attempt in 2025 was derailed by the Philippine Supreme Court, which blocked the process on a technicality before it could reach the Senate for trial. The case was revived earlier this year, and last week a House investigative committee concluded there was enough credible evidence to support moving forward with impeachment.

    Duterte has repeatedly dismissed the proceedings as a politically motivated sham. In a formal written statement responding to the committee’s ruling, she called the case “nothing more than a scrap of paper,” and refused to participate in the committee hearings, citing what she claims is a biased, partisan process.

    The lopsided House vote is widely seen as a clear demonstration of Marcos’ retained influence over the lower chamber of Congress. Unlike House members, who are elected by individual legislative districts and typically align with the sitting president to secure patronage and resources for their constituencies, the 24-member Senate is elected nationally and has long served as a launching pad for future presidential and vice presidential candidates.

    The path to a conviction remains far from certain, however. Half of the Senate seats were up for grabs in the 2025 midterm elections, and candidates aligned with Duterte outperformed those running under Marcos’ ruling coalition. In a political system defined by shifting dynastic alliances and flexible multi-party loyalties, forecasting the outcome of an impeachment trial is exceptionally difficult.

    For Duterte, a conviction would result in immediate permanent disqualification from holding any public office, scrapping her well-publicized plan to run for president in 2028. The 47-year-old politician, daughter of former Philippine President Rodrigo Duterte, currently holds a commanding lead in early presidential polling. A March 2026 survey by Manila-based pollster WR Numero placed her 17 percentage points ahead of her closest competitor.

    The current rift between Duterte and Marcos marks a dramatic reversal of fortune for the once-powerful political alliance that swept both into office in the 2022 national election. Duterte was originally the frontrunner to succeed her father as president in 2022, but agreed to run for vice president alongside Marcos to unify their support bases and block a rising reformist opposition. The ticket won election by a landslide, but the partnership quickly fractured as the two leaders pursued conflicting political agendas.

    Tensions boiled over after Marcos allies led by Romualdez launched an investigation into allegations of misappropriated funds in Duterte’s vice presidential office. During a fiery late-night online address at the height of the probe, Duterte openly stated she had instructed an associate that if she were killed, the associates should target Marcos, the first lady, and Romualdez.

    The relationship deteriorated further last March, when Marcos granted authority to the International Criminal Court to arrest former President Rodrigo Duterte, who is currently detained at The Hague awaiting trial on crimes against humanity charges linked to thousands of deaths during his controversial war on drugs.

  • Philippine House votes to impeach Vice President Sara Duterte

    Philippine House votes to impeach Vice President Sara Duterte

    In a major political shakeup that has sent shockwaves through the Philippines, the country’s House of Representatives delivered a historic vote on Monday, approving the impeachment of Vice President Sara Duterte by an overwhelming margin over a trio of serious allegations. The accusations leveled against Duterte include undeclared unexplained assets, the improper use of public government funds, and even threats to arrange the assassination of sitting President Ferdinand Marcos Jr.

    Dominance of Marcos Jr.’s political allies in the lower chamber shaped the final outcome, which landed at 255 votes in favor of impeachment to just 26 votes against, with nine lawmakers choosing to abstain from the historic ballot. Two separate impeachment complaints brought against the vice president will now advance to the Philippine Senate, where the upper legislative chamber will be convened as a formal impeachment tribunal to conduct Duterte’s trial.

    Duterte, who is the daughter of former Philippine President Rodrigo Duterte, one of the country’s most polarizing and influential modern political figures, has issued a general denial of all wrongdoing connected to the allegations. She has not, however, addressed the specific criminal claims brought against her in any public detailed response.

    This is not the first time the vice president has faced an impeachment vote: in 2023, the House similarly advanced impeachment proceedings against her, but Duterte avoided a Senate trial after the Supreme Court ordered the attempt halted on a constitutional technicality. It remains unclear whether the new impeachment attempt will face similar legal challenges, or if the Senate tribunal will move forward to weigh the merits of the accusations against the country’s second-highest elected official.

  • Bangladesh reach 93-2 at lunch on Day 4, lead Pakistan by 115 in first Test

    Bangladesh reach 93-2 at lunch on Day 4, lead Pakistan by 115 in first Test

    On the fourth day of the opening Test cricket fixture between Bangladesh and Pakistan, the hosts entered the lunch interval at 93 runs for the loss of two wickets, extending their overall lead over the visiting side to a solid 115 runs. The steady, determined batting performance from captain Najmul Hossain Shanto and veteran batter Mominul Haque laid the foundation for Bangladesh’s advantageous position after an early collapse put the team on the back foot early in the second innings.

    Bangladesh began the day smoothly, resuming their second innings at 7 runs without any losses. However, Pakistan’s fast bowling attack struck twice in quick succession to flip the early momentum. Pace bowler Mohammad Abbas trapped opener Mahmudul Hasan leg before wicket for a score of 5, breaking the first opening partnership. Shortly after, fellow pacer Hasan Ali claimed the second wicket, dismissing Shadman Islam for 10. Islam was caught off guard by an unexpected extra bounce from the delivery, and Saud Shakeel secured a clean catch at gully to end the batter’s innings. By the 11th over of the second innings, Bangladesh had been reduced to just 23 runs for two wickets, putting the hosts in a precarious position.

    Facing a potential collapse, Shanto and Mominul stepped up to rebuild the innings, repeating the stubborn rearguard performance they had delivered in Bangladesh’s first innings. The pair put together an unbeaten 70-run partnership for the third wicket, frustrating Pakistan’s bowling attack and dragging the hosts back into a commanding position. At the lunch break, Shanto – who had already notched up a century in Bangladesh’s first innings – remained unbeaten on 34 runs, while Mominul was also not out on 37 runs, holding firm against the tourists’ pressure.

    The solid second innings partnership puts Bangladesh on track to set a challenging target for Pakistan to chase in their final innings. Looking back at the match’s earlier proceedings, Bangladesh posted a strong first innings total of 414 after being bowled out, claiming a 27-run first innings lead after dismissing Pakistan for 386. Offspinner Mehidy Hasan was the star of Bangladesh’s first innings bowling performance, taking a five-wicket haul to dismantle the tourists’ batting line-up.